SYRE Stock: Price, Earnings History and SEC Filings
Spyre Therapeutics, Inc. (SYRE) last traded at $96.56, down 2.43% on the latest session and up 8.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.36 against an analyst estimate of $-0.71, a beat of 49.3%.
$96.56 -2.43%
1 month+8.46%
52-week high$110.18
52-week low$21.15
Volume661,126
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SYRE earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-0.36 | $-0.71 | +49.30% |
| Mar 2026 | May 5, 2026 | $-0.74 | $-0.66 | -12.12% |
| Dec 2025 | Feb 19, 2026 | $-0.70 | $-0.66 | -6.06% |
| Sep 2025 | Nov 4, 2025 | $-0.15 | $-0.68 | +77.94% |
SYRE beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for SYRE
SEC filing data is not available right now. You can search for SYRE on SEC EDGAR.
SYRE news
- Spyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data PreviewOct 24, 2026 · finance.yahoo.com
- Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS SaysOct 20, 2026 · finance.yahoo.com
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (SYRE) is a US-listed public company on Nasdaq.